AKT1 and cancer: Our results are in harmony with previous reports where rapamycin treatment has been shown to enhance autophagic activity in cancer cells by increasing LC3 II form and inhibiting the signaling of downstream molecules of the PI3K/Akt/mTOR pathway [29,30].